Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Search
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)
Hang Seng
17,417.68
(-2.03%)
Dow Jones
40,287.53
(-0.93%)
Nikkei 225
40,063.79
(-0.16%)
FTSE 100
8,155.72
(-0.6%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
66,838.08
(0.44%)
Oil
80.25
(-3.1%)
Gold
2,402.80
(-2.18%)
Lithium
41.42
(1.37%)
Iron Ore
104.4
(-1.03%)

PharmAust (ASX: $PAA) partners with berry consultants for phase 2/3 mnd study

PharmAust Limited partners with Berry Consultants for Phase 2/3 MND Study


PharmAust Limited (ASX: $PAA), a clinical-stage biotechnology company, has announced its partnership with leading clinical study design specialist Berry Consultants to design and analyse the planned adaptive Phase 2/3 clinical study for monepantel in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS).

PharmAust CEO's Commentary on Partnership with Berry Consultants


We are delighted to be working with Berry Consultants as their reputation and experience in designing and conducting the statistical analysis of MND/ALS studies is unmatched. Berry Consultants has partnered with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. The Center is currently running the largest ALS study ever undertaken, the Healey ALS Platform Trial, which is focused on accelerating the development of promising new drugs for patients with ALS. Berry Consultants was integral in the concept, design, and continual evolution of that study in addition to numerous other MND/ALS programs.

PharmAust's Partnership with Berry Consultants and Future Outlook


PharmAust Limited has partnered with Berry Consultants to design and analyse an adaptive Phase 2/3 clinical study for monepantel in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS). The collaboration aims to position monepantel for FDA approval for the treatment of MND/ALS. The company anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PharmAust is focused on repurposing monepantel for human neurodegenerative diseases and treating cancer in dogs, with the lead MPL program targeting the treatment of MND/ALS, a rare, incurable disease. Top-line results of the Phase 1 study in patients with MND/ALS are expected to be announced in Q1 CY2024.

Sourcehttps://announcements.asx.com.au/asxpdf/20240116/pdf/05zgkh9gzh85qg.pdf

Share to Social
0 Comments
Inline Feedbacks
View all comments

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions